Companies / ABBV vs REGN
ABBV vs REGN: AbbVie and Regeneron Pharmaceuticals
AbbVie (ABBV) reported $61.2B in revenue against a 6.9% net margin, while Regeneron Pharmaceuticals (REGN) reported $14.3B at a 31.4% net margin, most recently.
| Metric | ABBV | REGN |
|---|---|---|
| Revenue | $61.2B | $14.3B |
| Net Income | $4.2B | $4.5B |
| Gross Margin | 70.2% | — |
| Operating Margin | 24.6% | 24.9% |
| EPS (Diluted) | $2.36 | $41.48 |
| Free Cash Flow | $17.8B | $4.1B |
| Total Debt | $67.0B | $2.7B |
| P/E Ratio | 96.8× | 18.6× |
| P/B Ratio | n/m | n/m |
| Stock Price | $288.14 | $910.75 |
Free: last 5 years
| Fiscal year | FY2011 🔒 | FY2012 🔒 | FY2013 🔒 | FY2014 🔒 | FY2015 🔒 | FY2016 🔒 | FY2017 🔒 | FY2018 🔒 | FY2019 🔒 | FY2020 🔒 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ABBV Revenue | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $56.2B | $58.1B | $54.3B | $56.3B | $61.2B |
| REGN Revenue | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $16.1B | $12.2B | $13.1B | $14.2B | $14.3B |